0
Clinical Investigations: ASTHMA |

Fluticasone Propionate via the Diskhaler or Hydrofluoroalkane-134a Metered-Dose Inhaler on Methacholine-Induced Airway Hyperresponsiveness*

Stephen J. Langley, MBChB; Janet Holden, RGN; Alison Derham, DCR (R) MPPM; Paul Hedgeland, LRSC AIMgt; Raj K. Sharma, PhD; Ashley Woodcock, MD
Author and Funding Information

*From the Medicines Evaluation Unit (Dr. Langley, Mrs. Holden, and Mrs. Derham), Wythenshawe Hospital, Manchester; GlaxoSmithKline UK (Mr. Hedgeland and Dr. Sharma), Stockley Park, Uxbridge, Middlesex; and North West Lung Centre (Dr. Woodcock), Wythenshawe Hospital, Manchester, UK.

Correspondence to: Ashley Woodcock, MD, North West Lung Function Centre, Wythenshawe Hospital, Manchester, M23 9GP UK; e-mail: awoodcock@fs1.with.man.ac.uk



Chest. 2002;122(3):806-811. doi:10.1378/chest.122.3.806
Text Size: A A A
Published online

Study objectives: To compare the effect of 4 weeks of treatment with fluticasone propionate (FP), 100 μg bid, delivered either via the Diskhaler (GlaxoSmithKline; Middlesex, UK) or a hydrofluoroalkane (HFA)-134a pressurized metered-dose inhaler (pMDI) on airway responsiveness.

Design: A single-center, randomized, double-blind, double-dummy, placebo-controlled crossover study.

Setting: Outpatients.

Patients: Patients with mild asthma who had not received corticosteroids for 4 weeks prior to the study.

Interventions: FP, 100 μg bid, via the Diskhaler, HFA-134a pMDI, or placebo for periods of 4 weeks.

Measurements and results: The primary efficacy variable was the provocative dose of methacholine causing a 20% fall in FEV1 (PD20) at the end of each 4-week treatment period. The FP formulations were defined as equivalent if the treatment difference was within ± 1 doubling dose of methacholine. Forty-seven patients were included in the per-protocol population. The baseline PD20 geometric mean was 0.21 mg, which increased to 0.55 mg with FP via the HFA-134a pMDI and to 0.68 mg with FP via the Diskhaler. The treatment difference between adjusted means was − 0.16 doubling doses (95% confidence interval, − 0.62 to 0.31 doubling doses; p = 0.503). Both significantly decreased airway responsiveness compared to placebo (p < 0.001), and also significantly increased lung function with no difference between the two active groups. FP was well tolerated with few adverse events and no effect on serum cortisol levels.

Conclusions: FP delivered via the HFA-134a pMDI is equivalent to FP via the Diskhaler in reducing airway responsiveness.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543